Who are Voltron Therapeutics, Inc.'s investors?

Voltron Therapeutics, Inc.'s investors include Lucius Partners.

How much funding has Voltron Therapeutics, Inc. raised?

Voltron Therapeutics, Inc. has disclosed $9.4M raised across 4 rounds.

Where is Voltron Therapeutics, Inc. headquartered?

Voltron Therapeutics, Inc. is headquartered in New York, US.

Voltron Therapeutics, Inc.

New York, US · Founded 2017 · Delaware corporation · 1 known investors

Find your way into Voltron Therapeutics, Inc.

Biotech

Founders & leadership

Matthew DuffyPresident

Patrick GallagherChief Executive Officer

Matthew Eitner Named on SEC filingGeneral Partner at Lucius Partners

Anthony ZookNamed on SEC filing

Paul KornerNamed on SEC filing

James AhernNamed on SEC filingGeneral Partner at Lucius Partners

Investors · 1

Lucius PartnersinferredNew York

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$9.4M disclosed across 4 rounds · 2019–2022

▶$3.2MraisedNov 2023 · 63 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Matthew EitnerDirector
Paul KornerDirector
James AhernDirector
Anthony ZookDirector
Matthew DuffyExecutive Officer, Director
Patrick GallagherExecutive Officer, Director

Amount sold: $3.2M
Sales commissions: $385.3K
Placement agents: Laidlaw & Company (UK) Ltd.
First sale: Oct 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$300KraisedJun 2022 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James AhernDirector
Matthew EitnerDirector
Matthew DuffyExecutive Officer, Director
Patrick GallagherExecutive Officer, Director
Anthony ZookDirector
Paul KornerDirector

Offering amount: $5M
Amount sold: $300K
Sales commissions: $36K
Placement agents: Laidlaw & Company (UK) Ltd.
First sale: Jun 2022
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.5MraisedSep 2021 · 36 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James AhernDirector
Paul KornerDirector
Matthew DuffyExecutive Officer, Director
Matthew EitnerDirector
Anthony ZookDirector
Patrick GallagherExecutive Officer, Director

Offering amount: $12M
Amount sold: $2.5M
Sales commissions: $250.2K
Placement agents: Laidlaw & Company (UK) Ltd.
First sale: Aug 2021
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.3MraisedJul 2021 · 49 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Matthew DuffyExecutive Officer, Director
Matthew EitnerDirector
Anthony ZookDirector
Paul KornerDirector
James AhernDirector
Patrick GallagherExecutive Officer, Director

Offering amount: $3.3M
Amount sold: $3.3M
Sales commissions: $402K
Proceeds to insiders: $283.5K
Placement agents: Laidlaw & Company (UK) Ltd.
First sale: Oct 2019
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Voltron Therapeutics, Inc.'s investors?: Voltron Therapeutics, Inc.'s investors include Lucius Partners.
How much funding has Voltron Therapeutics, Inc. raised?: Voltron Therapeutics, Inc. has disclosed $9.4M raised across 4 rounds.
Where is Voltron Therapeutics, Inc. headquartered?: Voltron Therapeutics, Inc. is headquartered in New York, US.